Clinical Molecular Testing

Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). There are many different types of HPV. Some types can cause health problems including cervical cancer in women.

Evolution of Screening and Diagnosis

The mRNA testing technology distinguishes itself from the DNA testing technology in terms of clinical outcomes.^1,2,3

Disease Progression & mRNA Expression

HPV DNA levels may decrease, however, our assay targets E6/E7 mRNA, which increases with disease progression. HPV mRNA testing can screen for cervical carcinoma condition.⁴

The assay can identify 14 high-risk types (16/18/31/33/35/39/45/51/52/56/58/59/66/68) of HPV infections.

Liquid Based Cytology

HPV mRNA testing with ThinPrep specimen collection kit for greater patient comfort.

Vaginitis Screening 

Overlapping symptoms make vaginitis clinical diagnosis a challenge.¹

Co-infections and overlapping symptoms make clinical diagnosis a challenge. Up to 30% diagnosed with a BV co-infection are also co-infected with Candida species.

Some types of vaginitis are transferred through sexual activity, while others arise because of an imbalance in the bacterial or fungal makeup of the vaginal microbiome.2 Combined, bacterial vaginosis (BV), candida vaginitis (commonly known as a yeast infection, CV), and trichomoniasis (Trichomonas vaginalis, TV).

If these conditions are left untreated, it could l had to prolonged infection, increased risk of acquiring new STI and more long term conditions.^3,4

Chlamydia Trachomatis and Neisseria Gonorrhoeae (CTNG) Screening

Chlamydia (CT) and gonorrhea (NG) can have serious long-term consequences including pelvic inflammatory disease (PID), ectopic pregnancy and infertility. Testing and treatment are critical to protecting sexual and reproductive health.⁵